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Summary The potent kinase inhibitor staurosporine and its protein kinase C (PKC)-selective analogue
CGP 41251 are known to sensitise cells with the multidrug resistance (MDR) phenotype mediated by P-
glycoprotein (P-gp) to cytotoxic agents. Here four PKC-selective staurosporine cogeners, CGP 41251, UCN-01,
RO 31 8220 and GF 109203X, were compared with staurosporine in terms of their MDR-reversing properties
and their susceptibility towards P-gp-mediated drug efflux from MCF-7/Adr cells. Staurosporine was the most
potent and the bisindolylmaleimides RO 31 8220 and GF 109203X the least potent cytostatic agents. When
compared with MCF-7 wild-type cells, MCF-7/Adr cells were resistant towards the growth-arresting properties
of RO 31 8220 and UCN-01, with resistance ratios of 12.6 and 7.0 respectively. This resistance could be
substantially reduced by inclusion of the P-gp inhibitor reserpine. The ratios for GF 109203X, staurosporine
and CGP 41251 were 1.2, 2.0 and 2.9 respectively, and they were hardly affected by reserpine. These results
suggest that RO 31 8220 and UCN-01 are avidly transported by P-gp but that the other compounds are not.
Staurosporine and CGP 41251 at 10 and 20 nm, respectively, decreased efflux of the P-gp probe rhodamine 123
(R123) from MCF-7/Adr cells, whereas RO 31 8220 and GF 109203X at 640 nm were inactive. CGP 41251
was the most effective and GF 109203X the least effective inhibitor of equilibrium binding of [3H]vinblastine to
its specific binding sites, probably P-gp, in MCF-7/Adr cells. Overall, the results imply that for this class of
compound the structural properties that determine susceptibility towards P-gp-mediated substrate transport are
complex. Comparison with ability to inhibit PKC suggests that the kinase inhibitors affect P-gp directly and
not via inhibition of PKC. Among these compounds CGP 41251 was a very potent MDR-reversing agent with
high affinity for P-gp and least affected by P-gp-mediated resistance, rendering it an attractive drug candidate
for clinical development.
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Recent advances in the understanding of cellular signal
transduction pathways have led to the discovery of potent
inhibitors of protein kinases with cytostatic and chemosensi-
tising properties (Powis, 1992). Prominent among these
molecules is the indolocarbazole alkaloid staurosporine
(Figure 1), a natural product first isolated from Strepto-
myces staurosporeus (Omura et al., 1977). Staurosporine has
been the lead molecule for the synthesis of a variety of novel
kinase inhibitors, for example 7-hydroxystaurosporine (UCN-
01) and 4'-N-benzoyl staurosporine (CGP 41251), both of
which possess anti-cancer activity in rodents (Akinaga et al.,
1991; Meyer et al., 1989) (Figure 1). Replacement of the
indolocarbazole structure with the related bisindolylmalei-
mide system (Figure 1) furnished a series of staurosporine
cogeners exemplified by RO 31 8220 (Davis et al., 1992) and
GF 109203X (Toullec et al., 1991). A feature shared by
UCN-01, CGP 41251, RO 31 8220 and GF 109203X is that
they inhibit protein kinase C (PKC) selectively, whereas the
parent staurosporine molecule inhibits a variety of kinases
indiscriminately. Staurosporine (Sato et al., 1990; Sampson et
al., 1993) and CGP 41251 (Utz et al., 1994) have been shown
to sensitise cells with P-glycoprotein (P-gp)-mediated multi-
drug resistance (MDR) to cytotoxic agents. Therefore this
type of kinase inhibitor might be attractive as a chemother-
apeutic agent because of its MDR-reversing activity in
combination with cytostatic properties. UCN-01 and
CGP 41251 are currently in preparation for phase I clinical
evaluation as anti-cancer drugs.
The mechanisms by which staurosporine and its analogues
mediate their cytostatic and MDR reversing effects are
unclear. It is conceivable that strong, but non-selective,
kinase-inhibitory potency is a major determinant of activity
exerted by this type of agent. Alternatively high selectivity for
PKC, albeit coupled with weaker inhibitory potency, might
be required for optimal pharmacological efficacy. It is also
possible that cytostasis and MDR reversal are mediated by
mechanisms unrelated to kinase inhibition. We reported
recently that RO 31 8220 and GF 109203X are much less
potent inhibitors of the growth of A549 and MCF-7 cells
than staurosporine, UCN-01 and CGP 41251, whereas all five
compounds were strong inhibitors of the PKC contained in
these cells, with IC50 values of below 100 nM (Courage et al.,
1995). In the present study these five compounds are
compared as modifiers of P-gp-mediated MDR. Their
abilities to modulate the following three properties involving
P-gp were investigated in the human breast cancer-derived
multidrug-resistant MCF-7/Adr cell line: (1) growth of these
cells in contrast to that of their wild-type counterparts; (2)
binding of [3H]vinblastine to P-gp; and (3) cellular
accumulation and efflux of rhodamine 123 (R123) and
[3H]vinblastine. R123 has been shown to be a suitable
fluorescent probe for P-gp-mediated transport (Neyfakh,
1988; Efferth et al., 1989; Hofmann et al., 1992). The overall
objective of the work was to explore the mechanisms of
cytostasis and resistance reversal caused by kinase inhibitors
in a MDR cell line, with the ultimate aim to assess the
potential use of such compounds in cancer therapy.
Materials and methods
Chemicals, reagents and cells
UCN-01, RO 31 8220 and CGP 41251 were gifts from
Kyowa Hakko Kogyo Co. (Tokyo, Japan), Roche Research
Centre (Welwyn Garden City, UK) and Ciba Geigy (Basle,
Switzerland) respectively. GF 109203X was purchased from
Calbiochem-Novabiochem Co. (Nottingham, UK).
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[3H]Vinblastine (11 or 21 Ci mmol-') was obtained from
Amersham (Amersham, UK). Other chemicals and reagents
including staurosporine were obtained from Sigma Chemical
Co. (Poole, UK). Cell culture medium and serum were
purchased from Gibco BRL (Paisley, UK). Stock solutions of
drugs were prepared in dimethyl sulphoxide (DMSO) and
stored at -20°C. MCF-7 breast carcinoma cells and their
counterparts that have acquired stable resistance to doxor-
ubicin by exposure to the drug (MCF-7/Adr) were a gift from
J Carmichael (University of Nottingham, UK) and originally
derived inr the laboratory of K Cowan (NCI, Bethesda, MD,
USA). MCF-7 cells were also obtained from the European
Collection of Animal Cell Cultures (Salisbury, UK), and
these were indistinguishable from the above MCF-7 cells.
Cells were maintained routinely in an atmosphere of
oxygen-carbon dioxide (95:5), MCF-7 cells in minimum
essential medium (Eagle's modified) with fetal calf serum
(FCS) (10%), pyruvate (1 mM) and non-essential amino
acids, MCF-7/Adr cells in RPMI-1640 medium with heat-
inactivated FCS (10%). Cultures of both cell types contained
L-glutamine (2 mM), penicillin (100 IU ml-') and streptomy-
cin (100 ug ml-1). Cells were subcultured when they were
confluent.
Effect of staurosporine analogues on cell growth
Cells (2 x 104) were seeded in wells (35 mm diameter) with
3 ml of medium. After a 4 h attachment period compounds
at various concentrations were added. Cells were left for 4
days (four doubling times) with medium containing the
staurosporine analogue being replenished on day 2. Cells
were trypsinised and counted using a model ZM Coulter
counter. Incubations were conducted in duplicate. Growth
inhibition was expressed as percentage of cell number in
drug-free control incubates. In some experiments the effect of
the staurosporine analogues on cell growth was observed in
the presence of 5 gIM reserpine, which reverses MDR. At this
concentration reserpine did not interfere with proliferation.
IC50 values were derived from three separate experiments
each performed in duplicate. The resistance ratios shown in
Table I are the ratios of IC50 in MCF-7/Adr over IC50 in
MCF-7, or IC50 in MCF-7/Adr in the absence of reserpine
over IC50 in its presence.
Flow cytometric analysis of R123 accumulation and efflux
Cells were maintained in medium without phenol red but
with FCS (10%) and gentamicin (50 ,ug ml-'). Cells (106)
were allowed to attach for 1.5 h in dishes (55 mm diameter,
Falcon) with 3 ml of medium. Medium was replaced with
serum-free medium (5 ml) containing staurosporine analogue
(10-640 nM) and R123 (1.66 gM), and cells were incubated
for 20 min. Thereafter cells were either washed with
phosphate-buffered saline (PBS) (pH 7.4) and detached for
flow cytometric analysis of R123 accumulation, or processed
to determine R123 efflux as follows: cells were treated with
fresh serum-free medium (5 ml) without R123 but with
staurosporine analogue, and maintained for a further 20 min,
during which dye efflux occurred. Cells were detached by
treatment with trypsin-EDTA, washed with ice-cold PBS and
resuspended in PBS (1 ml), to which propidium iodide
(10 Mg) was added. Flow cytometric analysis was carried
out on a Becton Dickinson FACScan flow cytometer with the
excitation wavelength set at 488 nm. Fluorescence emission
caused by R123 or propidium iodide was measured after
passage through bandpass filters spanning 515-545 or 564-
H
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Figure 1 Structures of staurosporine and its four analogues used in this study.
Table I Inhibition of growth of MCF-7 and MCF-7/Adr cells by staurosponrne analogues and effect of reserpine
IC50a(#lM) Ratio ICso5(#M) Ratio
(MCF-7/Adr MCF-7/Adr + (-Reserpine
Compound MCF-7 MCF-7/Adr MCF-7) reserpineb + reserpine)
Staurosporine 0.0032 ±0.000lc 0.0065i0.0005*d 2.0 0.010+0.001 0.7
UCN-01 0.0175±0.001 0.123 i0.031 * 7.0 0.035+0.006*e 3.5
RO 31 8220 0.897+0.013 11.3 2.1*** 12.6 1.76+0.16**e 6.4
CGP 41215 0.097+0.012 0.283+0.015*d 2.9 0.31±0.03 0.9
GF 109203X 7.3±0.9 8.8±0.3 1.5 5.90+0.75 1.5
aConcentration whichcaused inhibition ofcellgrowthby 50%."The IC50 ofdoxorubicin in MCF-7/Adrcells was 1.6± 0.1 gM, in thepresence of
reserpine it was 0.10±0.01, which gave a ratio of 16. cMean± s.d. of three experiments. dDifference to MCF-7 cells. eDifference to MCF-7/Adr
without reserpine. *P<0.005. **P<0.001. ***P<0.0001.Effects of staurosporine analogues on MCF-7/Adr cells
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606 nm respectively. Single- and multi-parameter data of
forward angle scatter, side scatter, R123 fluorescence and
propidium iodide fluorescence were collected for 104 cells.
Fluorescence was measured on a four-decade log scale. The
data were analysed using Lysis 2 software. Only R123
fluorescence of viable, propidium iodide-excluding cells was
analysed.
[/II] Vinblastine accumndation ini cells
MCF-7 and MCF-7jAdr cells were grown to confluency in
12-well plates. Medium was replaced with Hepes-buffered
RPMI (pH 7.4) supplemented with magnesium chloride
(5 mM), glucose (5 mM) and staurosporine analogue
(300 nM). [3H]Vinblastine accumulation was estimated as
described previously (Ferry et al., 1995). The experiment
was started by addition of [3H]vinblastine (1-2 nM) to the
incubate. [3H]Vinblastine accumulation reached steady state
after 20 min and remained stable for at least 2 h. Cells were
incubated at 37'C for I h, after which the medium was
aspirated and replaced with scintillant (1 ml). Cell-free
control incubates showed that absorption of [3H]vinblastine
to the well constituted less than 50% of [3H]vinblastine
retained by cells.
/ -IH Vinhlastine binding to P-gp
[3H]Vinblastine binding to P-gp was assessed as described by
Ferry et al. (1992). For each membrane preparation 109 cells
were homogenised in 40 ml ice-cold Tris buffer [Tris-HC1
50 mM, phenylmethylsulphonyl fluoride (PMSF) 0.1 mM,
pH 7.4] to which 0.1 mM EDTA had been added. The
homogenate was centrifuged at 3500 g for 10 min; the
supernatant was recentrifuged at 40 000 g for 20 min, the
resultant pellet was resuspended in Tris buffer (10 ml). This
membrane pellet was enriched 3.1-fold in saturable
[3H]vinblastine binding relative to whole homogenate.
Membranes (5 -15 ,ig protein) were incubated for 90 min
with [3H]vinblastine (5 -10 nM) and staurosporine analogues
at various concentrations in Tris buffer (0.25 ml) at 23'C.
Bound [3H]vinblastine was separated from free drug by rapid
filtration through Whatman GF,'C filters prewetted with
buffer containing 0.1% bovine serum albumin (BSA). Filters
were washed twice with 5 ml of ice-cold Tris-HCI containing
magnesium chloride (both 20 mM). Assays were performed in
duplicate. Filters were dried and retained radioactivity was
quantitated by liquid scintillation counting. Filter blank
absorption under these conditions accounted for <0.5% of
total filtered radioactivity. These conditions yielded 5000-
10 000 d.p.m. total binding and 2000 5000 d.p.m. non-
specific binding, defined by 3,M unlabelled vinblastine.
Specific vinblastine binding was only observed in MCF-7/
Adr cells and not in their drug-sensitive counterparts (Ferry
et al., 1995). Binding data were modelled by non-linear
regression using the AR module of BMDP (BMDP Statistical
Software, USA) and Kaliedagraph (Ablebeck Software,
USA). [3H]Vinblastine binding inhibition curves were
analysed by non-linear curve fitting without transformation
of the data using d.p.m.
Results
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In order to explore whether the resistance mechanisms
operative in multidrug-resistant MCF-7/Adr cells affect the
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Figure 2 Effect of CGP 41251 on accumulation (a and b) and efflux (c and d) of R123 in MCF-7/Adr cells. Fluorescence
histograms were obtained in cells treated without (a and c) or with (b and d) CGP 41251 (80nM) for 20min together with R123 (a
and b) or for 20 min after initial loading with, and removal of, the dye (c and d).
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Figure 3 Comparison of the effects of staurosporine (C]), CGP
41251 (0), UCN-01 (0), RO 31 8220 and GF 109203X (U) on
accumulation (a) and efflux (b) of R123 in MCF-7/Adr cells.
Fluorescence histograms were obtained in cells treated without or
with agent for 20min together with the dye (a) or for 20min after
initial loading with, and removal of, the dye (b). Data are
presented as percentage change in comparison with control cells
and they constitute the mean+s.d. of three experiments. Values
for cells with CGP 41251, staurosporine and UCN-01 were
significantly different from control cells (P<0.05, Student's t-test)
in the case of all points except those for staurosporine at 10 and
20nM in a, and lOnM in b, and for UCN-01 at 80 and 160nM in
b.
antiproliferative potential of staurosporine and its four
analogues, compounds were incubated with cells and growth
inhibition was compared with that seen in wild-type MCF-7
cells. The IC50 values derived from the growth curves
are shown in Table I. Staurosporine was the most potent
cytostatic agent in both cell types. The rank order for
growth inhibition was staurosporine > UCN-01 >CGP
41521>RO 31 8220>GF 109203X in wild-type cells and
staurosporine > UCN-01>CGP 41521 >GF 109203X>
RO 31 8220 in drug-resistant cells. MCF-7/Adr cells dis-
played considerable resistance towards RO 31 8220 and
UCN-01, with resistance ratios of 12.6 and 7.0 respectively.
The cells were not resistant towards GF 109203X.
Modulation ofgrowth inhibition by reserpine
Reserpine is an effective modifier of P-gp-mediated cytotoxic
drug resistance (Pearce et al., 1989). In order to establish the
role ofP-gp in the resistance of MCF-7/Adr cells towards the
staurosporine analogues, cells were grown in the presence of
analogue and reserpine. In preliminary experiments reserpine
(5 gLM) was found to increase the sensitivity towards
doxorubicin 14.3-fold. Table I shows that reserpine
sensitised cells most effectively against RO 31 8220 and
UCN-01. Ratios of IC50s observed in cells without reserpine
compared with cells in its presence were 6.4 and 3.5 for
RO 31 8220 and UCN-01 respectively. In contrast, reserpine
did not change the sensitivity of MCF-7/Adr cells towards
CGP 41521 and had only a marginal effect on the cytostasis
mediated by staurosporine and GF 109203X. Furthermore,
reserpine did not affect the sensitivity of wild-type MCF-7
cells towards RO 31 8220 (result not shown).
Modulation of R123 accumulation and efflux and
[3H]vinblastine accumulation
For investigation of the effect of staurosporine and its
analogues on R123 accumulation and efflux, MCF-7/Adr
cells were incubated with R123 and kinase inhibitors and
analysed by flow cytometry. Flow cytometric analysis
detected two fluorescent populations in the control MCF-7/
Adr cells (Figure 2). These two subpopulations differ in P-gp
expression in that the cells with low R123 fluorescence
possess more P-gp activity than those which display high dye
(Davies et al., 1996). Figure 2 demonstrates the extent to
which CGP 41251 at 80 nm increased the accumulation of
R123 and decreased its efflux. In order to quantitate the
effects of the kinase inhibitors, combined mean fluorescence
values of both cell subpopulations in control and treated cells
were compared. Figure 3 summarises the effects on R123
accumulation and efflux. R123 levels were significantly
increased by 10 nM staurosporine and 20 nM CGP 41251.
At 80 nM.the increase over control levels in accumulation and
retention was 40+8% and 75+10% respectively for
staurosporine, and 47+ 12% and 150+62% respectively for
CGP 41521. Significant effects of UCN-01 were seen at 80 nM
on R123 accumulation and at 320 nm on dye efflux, whereas
RO 31 8220 and GF 109203X did not alter either R123
accumulation or efflux at 640 nm. Therefore, the rank order
of potency with respect to modulation of cellular R123 levels
by the kinase inhibitors is CGP 41251 = staurospor-
ine >UCN-01>RO 31 8220 = GF 109203X.
In order to confirm the results observed with R123 the
effect of the staurosporine analogues (300 nM) on the
accumulation of [3H]vinblastine into cells was studied.
Accumulation of [3H]vinblastine into MCF-7/Adr and
MCF-7 cells was rapid, reaching steady state by 30 min
(Hofmann et al., 1992). Consistent with the data described
for the experiments with R123 above, CGP 41251 increased
[3H]vinblastine accumulation in MCF-7/Adr cells from
1280+60 d.p.m. in control cells to 3200+ 160 d.p.m.
(mean+s.d. of 3 experiments). UCN-01 and GF 109203X
were less potent, raising [3H]vinblastine accumulation to
2110+90 and 1790+85 d.p.m. respectively. RO 31 8220 had
no effect. None of these agents at 300 nM affected
[3H]vinblastine accumulation in wild-type MCF-7 cells.
Inhibition of binding of [3H]vinblastine to P-gp
MCF-7/Adr cells overexpress P-gp (Fairchild et al., 1987).
Surface membrane preparations containing P-gp were
obtained from MCF-7/Adr cells and the ability of
staurosporine and its analogues to inhibit the binding of
[3H]vinblastine to P-gp was explored. Table II shows that
CGP 41521 was the most potent and GF 109203X the least
effective inhibitor of vinblastine binding, with Ki values of 32
Table H Inhibition of binding of [3H]vinblastine to P-gp
Compound Ki (nM)
CGP 41251 32±lla (6)b
Staurosporine 145 ±20 (4)
RO 31 8220 210+ 145 (3)
UCN-01 293 ± 120 (3)
GF 109203X 780i 190 (4)
aMeanis.e.m. bNumber ofexperiments in parenthesis.
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and 780 nM respectively. The rank order of inhibitory
potency was CGP 41251 >staurosporine > RO 31 8220 >
UCN-01>GF 109203X. Staurosporine and its analogues
are thought to bind to the ATP binding site of PKC.
Therefore we explored the possibility that addition of ATP
(1 mM) causes a shift in the binding inhibition curve of
CGP 41251 to P-gp. ATP did not have an effect, which
suggests that the drug did not bind to the ATP-binding
domain of P-gp (result not shown). The assay probes for
specific vinblastine binding sites, probably P-gp (Ferry et al.,
1995), but it has to be stressed that their identity is under
discussion and they may include sites other than P-gp.
Discussion
The results outlined above highlight considerable differences
in cytostatic and MDR reversing ability between kinase
inhibitors of the staurosporine type. In Table III these
differences are summarised and juxtaposed with the PKC-
inhibitory properties of these compounds. Our results show
that staurosporine, UCN-01, CGP 41251, RO 31 8220 and
GF 109203X differ 1300-fold in their cytostatic potency
against MCF-7/Adr cells, which contrasts markedly with
their abilities to inhibit PKC. In the case of PKC derived
from the cytosol of MCF-7 cells, IC50 values for enzyme
inhibition ranged only from 16 nm for staurosporine to
48 nM for RO 31 8220 (Courage et al., 1995).
The resistance observed in MCF-7/Adr cells against the
growth-inhibitory properties of RO 31 8220 and UCN-01 is
probably mediated by P-gp. This inference can be drawn
from the fact that sensitivity of the cells to the two drugs was
partially but significantly restored by inclusion of the P-gp
inhibitor reserpine into the cellular incubate. That reserpine
was unable to reverse resistance fully indicates that it might
have a similar binding affinity for P-gp as RO 31 8220 and
UCN-01. Alternatively, 5 gM reserpine might have been
insufficient to reverse resistance completely. Of the analogues
studied, staurosporine and CGP 41251 were the most potent
modulators of cellular R123 efflux and of vinblastine binding.
However, their cytostatic potential was affected only a little
by the presence of P-gp in the resistant cells. These results
suggest that, even although both agents have a high binding
affinity for P-gp, they are inefficiently transported by it. In
contrast, UCN-01 is probably efficiently transported by P-gp
as borne out by the resistance of MCF-7/Adr cells to it. Yet
UCN-01 has a low binding affinity for P-gp, allowing
reserpine to compete effectively for binding to P-gp and to
increase its cytotoxic potential in MCF-7/Adr cells.
RO 31 8220 displayed properties similar to those of UCN-
01, except that it was transported even more efficiently by P-
gp than UCN-01 as adjudged by the strong resistance which
MCF-7/Adr cells displayed against it. GF 109203X was
neither subject to P-gp-mediated resistance nor able to
influence R123 efflux. It was also the weakest inhibitor of
[3H]vinblastine binding to P-gp among this series of
compounds. Therefore GF 109203X seems to lack affinity
for P-gp and susceptibility for transport by P-gp. Interest-
ingly, GF 109203X has recently been shown to be an efficient
modulator of drug resistance mediated via the MDR-related
protein (Gekeler et al., 1995). One of the conclusions which
can be drawn from the differences between these compounds
(see Table III) is that the MDR-reversing ability of
staurosporine analogues appears to be linked to the
indolocarbazole structure. Consistent with this conclusion
are the results of a preliminary study in which the abilities of
CGP 41251 and RO 31 8220 to sensitise MCF-7/Adr cells
against doxorubicin were compared. The former at 80 nM
increased the sensitivity of cells towards doxorubicin by a
factor of 2, but the latter at 2 gM had no effect (J Budworth
and A Gescher, unpublished).
How can the differences between the compounds in
cytostatic potency and susceptibility towards the effect of
reserpine be integrated with those of the short-term assays of
R123 accumulation and efflux and [3H]vinblastine binding
(Table III)? Of the five compounds investigated, CGP 41251
has the highest affinity to the vinblastine binding site and is
hardly subject to resistance or modulation by reserpine. In
the light of the high affinity of CGP 41251 for P-gp, these
findings may reflect its long dwell time on its P-gp binding
site, suggesting that the pump transports the drug slowly. For
GF 109203X occupancy ofP-gp is likely to be low because of
its low affinity. UCN-01 and RO 31 8220, inhibitors with
medium affinity for P-gp, can occupy the pump and turnover
is high. RO 31 8220 was the most inconsistent of the five
molecules in that it did not modulate R123 efflux or
[3H]vinblastine accumulation, yet was subject to P-gp-
mediated resistance. The reasons for the observed differences
are undoubtedly complex. One variable which has not been
considered in the interpretation outlined above is the possible
effect of these kinase inhibitors on mdrl mRNA levels.
Transcription of the mdrl gene is stimulated through a c-raf
kinase pathway, which operates downstream from ras
(Cornwall and Smith, 1993). Staurosporine has recently
been reported to decrease mdrl expression (Bhat et al.,
1994; L McKinley and TW Gant, unpublished). Thus we
cannot exclude the possibility that the differences in growth-
inhibitory properties between MCF-7 and MCF-7/Adr cells
described above are a consequence of altered mdrl
expression, perhaps via kinase inhibition. Alternatively, in
the growth inhibition experiments described above, blockade
of P-gp at sub-growth inhibitory concentrations may have
elicited accumulation of an endogenous P-gp substrate that in
turn increased P-gp expression, thus attenuating the effects of
the compounds via a feedback mechanism. These possibilities
are currently under investigation.
One of the aims of this study was to probe for the link
between PKC inhibition and ability to inhibit P-gp. There
seems to be a close functional association between MDR and
PKC (O'Brian et al., 1989; Chambers et al., 1990), but the
mechanisms involved are unclear. Here we describe staur-
osporine as a potent growth inhibitor of MCF-7/Adr cells
and a good MDR-reversing agent. Staurosporine is one of
the most effective PKC inhibitors thus far discovered
(Tamaoki and Nakano, 1990), but arguably the least
selective of the five agents under investigation here. The
PKC-specific staurosporine cogeners used in this study share
similar PKC-inhibitory potency (Courage et al., 1995). Yet
the results described above suggest that these staurosporine
analogues differ dramatically in both ability to reverse P-gp-
mediated drug resistance and susceptibility towards transport
by P-gp. This discrepancy suggests that inhibition of total
Table III Summary of effects of staurosporine analogues
Resistance in MDR Inhibition of PKC inhibition
Effect on MCF-7/Adr reversal by [3H]vinblastine
Compound R123 efflux cells reserpine binding Potency Specificity
Staurosporine +a (+) +
UCN-01 (+) + + (+) + +
CGP 41215 + + + +
RO31 8820 + + (+) + +
GF 109203X + +
a+, potent effect; (+), weak effect; -, no effect.Effects of wo m _mquen- 7/Adr cea 1068-- J B et i
1068
PKC activity by these compounds is not a major mechanism
by which they modulate P-gp transport. A similar inference
has been drawn previously for staurosporine in other cell
types (Miyamato et al., 1993; Wasukawa et al., 1993).
In conclusion, the results presented here indicate that
selectivity for PKC is probably not a prerequisite for a
staurosporine analogue to possess MDR reversing properties
in cells which overexpress P-gp. These molecules differ
substantially in ability to bind to and to be transported by
P-gp. Among the five kinase inhibitors investigated the
indolocarbazoles CGP 412521 and staurosporine have the
highest affinity for P-gp but are transported only slowly.
Thus they possess the most suitable properties as MDR-
reversing agents. Of the two compounds, CGP 41251 is the
more attractive drug candidate for potential clinical use,
because it lacks the toxicity associated with staurosporine
(Meyer et al., 1989).
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